Once-Monthly GLP-1 RA Gan & Lee Pharmaceuticals Initiates Phase 3 GRADUAL-3
Gan & Lee initiated GRADUAL-3, the third large-scale Phase 3 clinical study of bofanglutide injection (GLP-1 RA) in adults with obesity or overweight.
Gan & Lee Pharmaceutical
Shanghai: 603087 ~$4B USD (mid-2026) MCAP
Gan & Lee Pharmaceuticals is a Chinese biopharmaceutical company specializing in insulin analogs and biosimilar peptides, with a leading share of China's domestic insulin market. In addition to its diabetes franchise, the company has expanded into metabolic disease and obesity with next-generation GLP-1 / dual-agonist programs. In June 2026, Gan & Lee reported positive Phase 3 results for its obesity peptide candidate and is preparing to expand outside of China through partnerships and licensing deals.
Company Info
Sector:Pharmaceutical / Metabolic Disease (Insulin and Peptide Therapeutics)
Headquarters:Beijing, China
Founded:1998
Website:www.ganlee.com/en/
Upcoming Milestones & Key Dates
H2 2026
Regulatory
NDA filing for obesity GLP-1 / glucagon dual agonist in China
Late 2026
Business Development
Western partnership / licensing announcements for obesity peptide
Clinical Development Pipeline
GLP-1 / glucagon dual agonist (obesity)
Target: GLP-1 / glucagon receptor dual agonistInsulin glargine biosimilar
Target: Long-acting basal insulin analogNext-generation insulin / peptide combinations
Target: Co-formulated basal insulin + GLP-1 / dual agonistRecent News
Leadership Team
Wei Chen, Ph.D.
Chairman and President
Gan Zhongru (Zhong Ru Gan)
Founder and Chairman (former)
Careers & Job Openings